Brii Biosciences Ltd. shared interim data from a phase III trial of its neutralizing monoclonal antibody (mAb) combination therapy for SARS-CoV-2, BRII-196 and BRII-198, that showed a 78% reduction in the risk of hospitalization or death in patients receiving single dose of the cocktail.

Data presented at the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics, including Hummingbird Bioscience.

Data presented at IDWeek 2021, including: Allovir, Codagenix, Humanigen, Neoleukin.

Data to be presented at ESMO Congress 2021, including: Astellas, Astrazeneca, Carsgen, Cstone, Daiichi Sankyo, Pfizer.

Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.

Data to be presented at ESMO Congress 2021, including: Acepodia, Bridge, Coherus, Cstone, Daiichi Sankyo, Eqrx, Junshi, Laekna Therapeutics Shanghai, Sarah Cannon Research Institute.

Data to be presented at ESMO Congress 2021, including: Harbour Biomed, Samsung Bioepis.

Cell and gene therapy have seen much progress in recent times, with the product pipelines in those areas bursting with more than 1,200 therapies. Naturally, the challenges, opportunities and essential development strategies in those fields were the focus on the last day of the BIO Asia-Taiwan Conference 2021.

The biotech industry in Asia is a promising market, but it still has a long way to go to narrow the gap between Asian and Western markets, according to speakers on day two of the BIO Asia-Taiwan Conference 2021.

Financing is the fuel that drives growth in the biopharma sector, and participants at the BIO Asia-Taiwan Conference 2021 this week discussed different financing strategies for companies in the currently booming market.